A major randomized trial challenges the postulated benefits of cytoreduction in advanced colorectal cancer, showing no survival benefit despite increased risk, raising questions about the role of cytoreduction in routine treatment.
Study: Tumor debulking in combination with chemotherapy in multisystem metastatic colorectal cancer. Image credit: 3dMediSphere/Shutterstock.com
Tumor debulking combined with standard first-line palliative chemotherapy does not improve survival outcomes for patients with multisystem metastatic colorectal cancer (mCRC) over chemotherapy alone, according to a study published today. Japan Automobile Manufacturers Association.
Can weight loss extend its benefits to widespread metastases?
Colorectal cancer (CRC) remains one of the most commonly diagnosed malignancies worldwide and a leading cause of cancer-related deaths. Despite advances in screening and treatment, up to half of patients eventually develop metastatic disease, with significantly worse outcomes.
However, in selected patients with limited metastatic spread, aggressive local treatments such as surgical resection and thermal ablation have changed the prognosis. Although these approaches can achieve 5-year survival rates of 35% to 65%, parallel advances in systemic therapy have resulted in median overall survival exceeding 30 months.
Based on these successes, there is growing interest in extending local treatment strategies to a wider range of metastatic colorectal cancer (mCRC) patients, including tumor debulking in parallel with systemic chemotherapy. However, whether such approaches provide a meaningful survival benefit for patients with multisystem metastatic disease remains uncertain due to limited evidence from prospective randomized trials.
ORCHESTRA Trial Test Delivers Advanced mCRC Weight Loss
Researchers conducted the ORCHESTRA trial, a randomized, open-label, phase 3 clinical trial in 382 patients with mCRC. Most were treated at hospitals in the Netherlands. All patients had tumors that could be debulked by at least 80% at prerandomization evaluation before starting first-line palliative chemotherapy. The purpose of this study was to determine whether weight loss increases overall survival by at least 6 months.
Before randomization, all patients received initial chemotherapy with standard colorectal cancer drugs. Only participants who responded to chemotherapy or had stable disease continued in the study. Participants were then randomly assigned to receive either chemotherapy alone or chemotherapy plus debulking.
The aim of the study was to assess whether additional dose reduction could extend overall survival by at least 6 months. Additionally, the researchers evaluated survival in subgroups stratified by various tumor markers, including CEA and BRAF V600E, and assessed prognostic associations with survival outcomes.
Addition of tumor debulking does not prolong survival
Participants in both groups were predominantly male. Overall, the study found no significant differences in overall survival or progression-free survival between patients who received chemotherapy alone and chemotherapy plus cytoreduction. However, the addition of dose reduction was associated with an increased toxic burden, with a 14.62 percentage point increase in serious adverse events (53% vs. 39%). These findings do not support the assumption that local treatment can reduce chemotherapy-related toxicity by delaying or interrupting systemic therapy. Of note, quality of life outcomes were similar in both treatment groups.
Treatment exposure also differed between groups. In the debulking group, fewer patients completed at least 6 months of chemotherapy compared with patients receiving chemotherapy alone. The authors suggest that this may reflect factors such as disease progression during local treatment or decreased ability or unwillingness to resume systemic treatment after debulking procedures.
The study population represents a specific subgroup of patients with multisystem metastatic CRC, and the results may not be directly applicable to patients with more limited metastatic disease. Yet, a subgroup analysis of patients with metastases confined to the liver or lungs did not demonstrate an overall survival benefit with dose reduction. However, the authors emphasize that the trial was not designed or powered to conclusively evaluate outcomes in these more restricted subgroups.
Consistent with the overall findings, progression-free survival was similar between treatment groups, as observed in previous studies. Although this suggests that reducing tumor burden with debulking may not slow disease progression, the authors cautioned against overinterpretation, especially in patients with less extensive disease, where the trial lacked statistical power.
One exploratory subgroup analysis suggested an overall survival advantage for patients with stable disease at randomization. However, this signal was difficult to interpret because it was not accompanied by a corresponding improvement in progression-free survival, limiting its clinical significance.
Research limitations
Although this study compared two subgroups, the 10-year recruitment period may have weakened its conclusions, and the success rate may have been reduced because the indicators were outdated and modern chemotherapy regimens were not used.
Nevertheless, both groups experienced these limitations, and therefore the overall findings are unlikely to change.The authors note that survival outcomes were broadly consistent with more recent first-line chemotherapy trials, suggesting that these factors are unlikely to significantly alter the study’s conclusions.
Weight loss increases risk without increasing survival
This study shows that cytoreduction and systemic chemotherapy do not improve overall survival in mCRC patients compared with chemotherapy alone and may increase the risk of severe side effects. Based on these findings, such an approach is not supported for routine use.
The authors comment: “These results highlight the importance of prospective randomized clinical trials when considering the role of local therapy in the treatment of mCRC patients.”
Click here to download your PDF copy.
